575 filings
Page 3 of 29
6-K
gs7djct6p9q67qun
3 Aug 22
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
5:27pm
6-K
clb8h5tiy905j
3 Aug 22
Condensed Interim Consolidated Financial Statements
5:14pm
6-K
q5ku14 i1403va
26 Jul 22
Material Change Report
3:49pm
6-K
fupk1bk
19 Jul 22
Current report (foreign)
4:52pm
6-K
icb5etwzr
18 Jul 22
Aeterna Zentaris Announces Effective Date of Share Consolidation
5:29pm
6-K
iwoo0o
15 Jul 22
Current report (foreign)
4:15pm
6-K
dbwe2r
6 Jul 22
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
4:05pm
6-K
8u6ugut22m432x37blq7
21 Jun 22
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
4:12pm
6-K
ozu74qedi3cdivo
21 Jun 22
Report of Voting Results
4:04pm
6-K
hrc2k3
31 May 22
Annual General and Special Meeting of Shareholders
6:12am
6-K
8v232g6l93wa n7b
17 May 22
Current report (foreign)
3:04pm
6-K
edtkjlui
16 May 22
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation
2:14pm
6-K
wfz4zrzs80zaxmauedi
11 May 22
Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook
7:48pm
6-K
z2q9qr2m
10 May 22
Current report (foreign)
7:18pm
6-K
0bmfw9 jdezl7df
19 Apr 22
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
8:45pm
6-K/A
8rc4bjvq
31 Mar 22
Consolidated Financial Statements
4:05pm
6-K
pgo7 wb52
29 Mar 22
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook
8:10am
6-K
mf577ze6nf 25f4ad
28 Mar 22
Consolidated Financial Statements
9:35pm
6-K
xiptvoa
10 Mar 22
Current report (foreign)
6:21pm
6-K
g82bk7btn2i k0
2 Mar 22
Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism
8:15am